BioInvent International restructures its portfolio to prioritize BI-1206 and BI-1808, two antibody programs with strong clinical data. BI-1206, an FcγRIIB-blocking antibody, will enter a Phase IIa study for first-line treatment of NSCLC in H2 2025, while BI-1808, an anti-TNFR2 antibody, is advancing in Phase IIa for solid tumors and CTCL. The development of BI-1910 and BI-1607 is paused, and BT-001 continues to be developed in an investigator-led study in collaboration with Transgene. In connection with this, the workforce will be reduced by approximately 25 positions and the company expects cash to finance operations until Q1 2027.
|
Published August 26, 2025
BioInvent pauses development – focuses on leading programs
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account